Government-performed comparative drug studies are bad because the results not only affect Medicare but the private market as well, writes American Enterprise Institute fellow Scott Gottlieb in an op-ed for the Wall Street Journal. A provision for a new federal center to study the economics of drug choices (part of the State Children's Health Insurance Program) will give misleading results and the data will not be transparent, argues Gottlieb, drawing on past studies such as

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.